Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL6000280

CCC(c1ccncc1)c1cccc(Cl)c1.N

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 3/20 0.51
SLC6A2 P23975 2/20 0.42
SLC6A4 P31645 2/20 0.42
SLC6A3 Q01959 2/20 0.42
S1PR1 P21453 1/20 0.41
MAPK3 P27361 1/20 0.40
MAPK1 P28482 1/20 0.40
ALDH1A1 P00352 1/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39
OPRM1 P35372 2/20 0.39
OPRD1 P41143 2/20 0.39
OPRK1 P41145 2/20 0.39
OPRL1 P41146 2/20 0.39
CYP19A1 P11511 2/20 0.38
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38
HTR6 P50406 1/20 0.37
PDE4A P27815 1/20 0.37
ACP3 P15309 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL5999329 0.88 OPRM1 (0.44) SLC6A2SLC6A4SLC6A3MAPK1OPRM1
SCHEMBL17071892 0.86 ACP3 (0.47) SLC6A2SLC6A4MAPK1ALDH1A1OPRM1
SCHEMBL16771227 0.86 ACP3 (0.46) SLC6A2SLC6A4MAPK1OPRM1OPRD1
Ammonia Solution, Strong SCHEMBL5999965 0.85 CYP17A1 (0.49) CYP17A1SLC6A2SLC6A4SLC6A3S1PR1
Ammonia Solution, Strong SCHEMBL5999726 0.84 KCNA5 (0.52) SLC6A2SLC6A4SLC6A3OPRM1OPRD1
Ammonia Solution, Strong SCHEMBL5999712 0.82 SLC6A3 (0.59) CYP17A1SLC6A2SLC6A4SLC6A3S1PR1
SCHEMBL3398977 0.82 HTR2A (0.48) SLC6A2SLC6A4SLC6A3CYP19A1CYP11B1
Ammonia Solution, Strong SCHEMBL6000279 0.82 CYP17A1 (0.52) CYP17A1SLC6A2SLC6A4SLC6A3S1PR1
Ammonia Solution, Strong SCHEMBL5999692 0.81 CYP19A1 (0.59) CYP17A1SLC6A2SLC6A4SLC6A3OPRK1
Ammonia Solution, Strong SCHEMBL5999442 0.81 CYP17A1 (0.51) CYP17A1SLC6A2SLC6A4SLC6A3S1PR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060058357-A1 Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke K AND K BIOSCIENCE, INC. (US) 2006-03-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058357-A1 Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke SIGMAR1, GRM1, GRIN2C CYP17A1 4384/4885SLC6A2 1494/4885SLC6A4 1569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.